GO:0030250 guanylate cyclase activator activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030250 (guanylate cyclase activator activity) is a molecular function defined as binding to and increasing the activity of guanylate cyclase [QuickGO].
• Activators of soluble guanylate cyclase (sGC) such as YC-1 and runcaciguat (BAY 1101042) stimulate cGMP production independently of nitric oxide, making them attractive pharmacological tools [2, 5].
• Guanylate cyclase activator activity is essential in sperm function, where cGMP signaling controls motility and the acrosome reaction.
• The term is distinct from guanylate cyclase stimulators, which require the heme moiety of sGC, whereas activators can act on heme-free or oxidized enzyme [4, 6].
• Dysregulated cGMP signaling is implicated in cardiovascular disease, bone remodeling, and platelet dysfunction, making this GO term relevant to multiple pathologies [3, 5].
• CRISPR-based knockout, point-mutation, and knock-in models are powerful tools to dissect the causal role of guanylate cyclase activator proteins in health and disease.
Description
Guanylate cyclase activator activity (GO:0030250) is a molecular function that describes the binding to and increase of guanylate cyclase activity, a key step in the production of cyclic guanosine monophosphate (cGMP) [QuickGO]. This activity is central to numerous physiological processes, including smooth muscle relaxation, platelet inhibition, and sperm function [1, 5]. Unlike guanylate cyclase stimulators, which enhance enzyme activity in a heme-dependent manner, activators can directly stimulate the enzyme even when its heme group is oxidized or absent, offering a unique pharmacological profile [4, 6]. The term is particularly relevant for researchers studying nitric oxide (NO)-independent cGMP signaling, as it provides a mechanism to bypass impaired NO pathways in disease states [2, 6]. The importance of guanylate cyclase activator activity extends to drug discovery. Small-molecule activators such as YC-1 and runcaciguat have been developed to treat cardiovascular conditions, and their mechanisms are intensely studied [2, 5]. In reproductive biology, guanylate cyclase activity is critical for sperm capacitation and motility, highlighting the term's broad biological significance. Additionally, nutritional and pharmacological strategies targeting soluble guanylate cyclase are being explored for bone health and metabolic disorders. For biomedical researchers, understanding GO:0030250 requires integrating structural biology, enzymology, and cell signaling. The availability of CRISPR-engineered cell models now allows precise interrogation of the genes encoding guanylate cyclase activator proteins, accelerating both basic and translational research.
guanylate cyclase activator activity At A Glance
| GO ID | GO:0030250 |
|---|---|
| GO term | guanylate cyclase activator activity |
| Ontology | molecular_function |
| Synonym | guanylin |
| Major function | Binds to and increases the activity of guanylate cyclase, promoting cGMP synthesis |
| Related enzymes | Soluble guanylate cyclase (sGC), particulate guanylate cyclase (pGC) |
| Key activators | YC-1, runcaciguat (BAY 1101042), guanylin peptides |
| Pathological relevance | Cardiovascular disease, platelet dysfunction, bone remodeling, sperm dysfunction |
What Is GO:0030250?
According to the Gene Ontology, guanylate cyclase activator activity (GO:0030250) is a molecular function defined as binding to and increasing the activity of guanylate cyclase. This activity is mediated by proteins or small molecules that interact with guanylate cyclase enzymes, leading to enhanced conversion of GTP to cGMP. The term is synonymous with guanylin, a peptide that activates guanylate cyclase in the intestine. It is distinct from guanylate cyclase stimulator activity, which typically requires the heme group of soluble guanylate cyclase for action [4, 6].
Why Is guanylate cyclase activator activity Important in Cell Biology?
Guanylate cyclase activator activity is a cornerstone of cGMP-mediated signaling, which regulates vascular tone, platelet aggregation, and neuronal plasticity. Pharmacological activation of guanylate cyclase offers a therapeutic strategy for conditions where nitric oxide signaling is impaired, such as heart failure and pulmonary hypertension [2, 4]. Moreover, this activity is essential for male fertility, as cGMP produced by guanylate cyclase activation drives sperm motility and the acrosome reaction. Understanding the molecular players and their regulation can reveal new drug targets and biomarkers.
• Regulates smooth muscle relaxation and vasodilation, impacting blood pressure control.
• Inhibits platelet aggregation, reducing thrombosis risk.
• Essential for sperm motility and capacitation, affecting male fertility.
• Modulates bone remodeling, with implications for osteoporosis.
• Provides a NO-independent pathway to elevate cGMP in disease states.
• Serves as a target for drugs like riociguat and vericiguat in cardiovascular medicine.
• Involved in intestinal fluid secretion via guanylin peptides [QuickGO].
• Plays a role in neuronal signaling and neuroprotection.
• Can be studied using CRISPR knockout models to establish causality.
• Offers a paradigm for allosteric enzyme regulation.
Molecular Mechanism of guanylate cyclase activator activity
Binding of Activators to Guanylate Cyclase
In simple terms: Activator molecules attach to the guanylate cyclase enzyme, causing it to change shape and become more active.
Guanylate cyclase activators, such as YC-1, bind directly to the catalytic domain or allosteric sites of soluble guanylate cyclase (sGC), inducing a conformational change that enhances catalytic efficiency. This binding is independent of the heme group, allowing activation even under oxidative stress. The interaction increases the Vmax of the enzyme without affecting substrate affinity.
Catalytic Conversion of GTP to cGMP
In simple terms: Once activated, the enzyme converts GTP into cGMP, a key signaling molecule.
Activated guanylate cyclase catalyzes the cyclization of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP) and pyrophosphate. This reaction requires divalent cations, typically Mg2+ or Mn2+, as cofactors. The produced cGMP then acts as a second messenger, activating protein kinase G (PKG) and other effectors.
Regulation by Endogenous Peptides
In simple terms: Natural peptides like guanylin can also turn on guanylate cyclase in specific tissues.
Endogenous guanylin peptides, such as guanylin and uroguanylin, act as physiological activators of particulate guanylate cyclase (pGC) in the intestine and kidney. Their binding to pGC increases cGMP production, which regulates ion and water secretion [QuickGO]. This mechanism is distinct from that of soluble guanylate cyclase activators, which are small synthetic molecules.
Cofactors and Structural Requirements
In simple terms: The enzyme needs certain metal ions and a specific structure to work properly.
Guanylate cyclase activity requires divalent cations, with Mg2+ being the preferred cofactor in vivo. The enzyme's catalytic domain contains a conserved motif that coordinates these ions. Activators may stabilize the active conformation or enhance metal binding. In contrast to stimulators, activators do not require the heme prosthetic group, which is why they can activate oxidized or heme-deficient sGC.
Downstream Signaling and Physiological Effects
In simple terms: The cGMP produced triggers a cascade of effects, like relaxing blood vessels or changing sperm behavior.
Elevated cGMP activates protein kinase G (PKG), which phosphorylates targets to reduce intracellular calcium and cause smooth muscle relaxation. In platelets, cGMP inhibits aggregation. In sperm, cGMP signaling is required for motility and the acrosome reaction. These diverse effects underscore the broad physiological importance of guanylate cyclase activator activity.
Key Genes Involved in GO:0030250 guanylate cyclase activator activity
The following genes and proteins are directly involved in guanylate cyclase activator activity or its downstream signaling, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GUCY1A1 | Alpha subunit of soluble guanylate cyclase | Target of activators; mutations linked to cardiovascular disease |
| GUCY1B1 | Beta subunit of soluble guanylate cyclase | Heme-binding subunit; essential for NO responsiveness |
| GUCY2C | Intestinal guanylate cyclase | Receptor for guanylin; target in colorectal cancer |
| GUCY2D | Retinal guanylate cyclase | Mutations cause Leber congenital amaurosis |
| GUCA1A | Guanylate cyclase activator 1A | Calcium-binding protein; regulates photoreceptor guanylate cyclase |
| GUCA1B | Guanylate cyclase activator 1B | Similar to GUCA1A; involved in retinal function |
| GUCA2A | Guanylin | Endogenous activator of GUCY2C; regulates fluid secretion |
| GUCA2B | Uroguanylin | Activates GUCY2C in kidney and intestine |
| PRKG1 | cGMP-dependent protein kinase 1 | Mediates downstream effects of cGMP |
| PRKG2 | cGMP-dependent protein kinase 2 | Involved in intestinal secretion and bone remodeling |
| PDE5A | Phosphodiesterase 5A | Degrades cGMP; modulates activator effects |
| NPPA | Atrial natriuretic peptide | Activates particulate guanylate cyclase |
| NPPB | Brain natriuretic peptide | Activates particulate guanylate cyclase |
| NPR1 | Natriuretic peptide receptor 1 | Guanylate cyclase-coupled receptor |
| NPR2 | Natriuretic peptide receptor 2 | Guanylate cyclase-coupled receptor |
| HMOX1 | Heme oxygenase 1 | Influences heme availability for sGC |
| CYS | Cystathionine gamma-lyase | Produces H2S, which can modulate sGC activity |
How Is guanylate cyclase activator activity Regulated?
Guanylate cyclase activator activity is regulated at multiple levels. The expression and stability of guanylate cyclase subunits are controlled by transcription factors and microRNAs. Post-translational modifications, such as phosphorylation and S-nitrosylation, can modulate enzyme sensitivity to activators. Additionally, the availability of cofactors like heme and divalent cations affects the efficacy of activators. Phosphodiesterases (PDEs) rapidly degrade cGMP, thereby limiting the duration of activator effects. In pathological conditions, oxidative stress can oxidize the heme group, rendering stimulators ineffective but preserving the action of activators.
guanylate cyclase activator activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GUCY1A1 | Hypertension, heart failure | Knockout mouse, hiPSC-derived cardiomyocytes |
| GUCY2C | Colorectal cancer, secretory diarrhea | Intestinal organoids, KO mice |
| GUCA1A | Retinal degeneration | Retinal organoids, knock-in mice |
| PRKG1 | Thoracic aortic aneurysm | Smooth muscle cell KO |
| PDE5A | Erectile dysfunction, pulmonary hypertension | Overexpression cell lines |
Cardiovascular Disease
Impaired nitric oxide-cGMP signaling is a hallmark of heart failure, pulmonary hypertension, and atherosclerosis. Guanylate cyclase activators like runcaciguat can bypass NO deficiency and restore cGMP levels, improving vascular tone and cardiac function [2, 6]. Clinical trials are evaluating these compounds for chronic kidney disease and heart failure.
Platelet Disorders and Thrombosis
YC-1, a prototypical guanylate cyclase activator, inhibits platelet aggregation by elevating cGMP. This suggests that activators could be used as antiplatelet agents, particularly in patients resistant to NO-based therapies.
Male Infertility
Guanylate cyclase activity is essential for sperm motility and the acrosome reaction. Defects in cGMP signaling are associated with asthenozoospermia. Activators may have therapeutic potential in assisted reproduction, though further research is needed.
Bone Remodeling and Osteoporosis
cGMP signaling promotes osteoblast differentiation and bone formation. Nutraceuticals that activate soluble guanylate cyclase, such as those targeting Sirt1 and AMPK, have been proposed to preserve bone mass. This highlights a potential role for guanylate cyclase activators in osteoporosis management.
From guanylate cyclase activator activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GUCY1A1 mediate activator-induced cGMP increase? | CRISPR knockout of GUCY1A1 in HEK293 or HUVEC cells |
| What is the effect of a point mutation in the catalytic domain? | Point-mutation knock-in via CRISPR in cell lines |
| Can we tag endogenous guanylate cyclase for imaging? | Knock-in of fluorescent tag (e.g., GFP) at GUCY1A1 locus |
| Does overexpression of GUCA2A enhance cGMP signaling? | Overexpression lentiviral vector in intestinal cells |
| Which genes are essential for activator response? | Genome-wide CRISPR library screening |
| How does a disease-associated SNP affect activator sensitivity? | Isogenic point-mutation cell lines |
How to Study the guanylate cyclase activator activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| cGMP ELISA | Intracellular or extracellular cGMP levels | Quantifying activator potency |
| Radioimmunoassay | cGMP production from GTP | Enzyme kinetics |
| FRET-based cGMP sensor | Real-time cGMP dynamics | Live-cell imaging |
| CRISPR knockout screen | Genes required for activator response | Target discovery |
| RNA-seq | Transcriptional changes | Pathway analysis |
| Phosphoproteomics | Protein phosphorylation events | Downstream signaling |
| Surface plasmon resonance | Binding affinity of activators to sGC | Mechanistic studies |
Biochemical Assays for Guanylate Cyclase Activity
Enzymatic activity of guanylate cyclase can be measured using radioimmunoassays or ELISA to quantify cGMP production from GTP in cell lysates or purified enzyme preparations. These assays are used to screen for novel activators and to characterize their potency and mechanism.
Cell-Based cGMP Imaging
Genetically encoded cGMP sensors (e.g., cGi500) allow real-time monitoring of intracellular cGMP dynamics in living cells. This method can reveal the spatiotemporal effects of activators and is compatible with high-content screening.
CRISPR Screening for Modulators
Genome-wide CRISPR knockout or activation screens can identify genes that regulate sensitivity to guanylate cyclase activators. Such screens have uncovered novel components of the cGMP pathway and potential drug targets.
Transcriptomics and Proteomics
RNA-seq and mass spectrometry-based proteomics can profile changes in gene expression and protein phosphorylation downstream of guanylate cyclase activation. These approaches help elucidate the broader signaling network and identify biomarkers.
How CRISPR Can Be Used to Study GO:0030250 guanylate cyclase activator activity
Knockout
CRISPR-Cas9 knockout of genes encoding guanylate cyclase subunits (e.g., GUCY1A1) or activator proteins (e.g., GUCA1A) can abolish activator responses, establishing causality. These models are essential for validating drug targets and understanding resistance mechanisms.
Point Mutation
Introducing disease-associated point mutations (e.g., in GUCY1A1) via CRISPR base editing or homology-directed repair allows researchers to study how specific amino acid changes affect activator binding and catalytic activity. Such models mimic human genetic variants.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) or epitope tags at endogenous loci enables visualization and purification of guanylate cyclase complexes. This approach preserves native regulation and can reveal subcellular localization.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of guanylate cyclase activators (e.g., GUCA2A) can enhance cGMP signaling, providing gain-of-function models to study downstream effects and potential therapeutic applications.
How EDITGENE Supports guanylate cyclase activator activity Research
Researchers studying guanylate cyclase activator activity-related genes often need to determine whether a candidate gene is causally involved in cGMP signaling, disease progression, or drug response. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional studies.
Contact EDITGENE today to design your custom CRISPR model for guanylate cyclase activator activity research.
Frequently Asked Questions About guanylate cyclase activator activity
What is guanylate cyclase activator activity?
It is a molecular function (GO:0030250) defined as binding to and increasing the activity of guanylate cyclase, leading to increased cGMP production [QuickGO].
What genes are involved in guanylate cyclase activator activity?
Key genes include GUCY1A1, GUCY1B1, GUCY2C, GUCA1A, GUCA1B, GUCA2A, and GUCA2B, among others [1, 2, 4].
How does guanylate cyclase activator activity differ from stimulator activity?
Activators can stimulate guanylate cyclase independently of its heme group, whereas stimulators require heme and act synergistically with NO [4, 6].
What diseases are associated with guanylate cyclase activator activity?
Cardiovascular disease, platelet disorders, male infertility, and bone remodeling disorders [1, 2, 3, 5].
What are examples of guanylate cyclase activators?
YC-1 and runcaciguat (BAY 1101042) are well-known synthetic activators [2, 5].
How can I study guanylate cyclase activator activity in the lab?
Use biochemical cGMP assays, live-cell imaging with cGMP sensors, and CRISPR knockout models to test causality [4, 6].
What is the role of guanylate cyclase activator activity in sperm?
It regulates cGMP levels necessary for sperm motility and the acrosome reaction.
Can CRISPR be used to study guanylate cyclase activator activity?
Yes, CRISPR knockout, point mutation, and knock-in models are powerful tools to dissect gene function in this pathway [4, 6].
What is the synonym for GO:0030250?
The synonym is guanylin [QuickGO].
Which cell models are best for studying guanylate cyclase activator activity?
HEK293, HUVEC, platelets, sperm cells, and intestinal organoids are commonly used, depending on the specific gene and pathway [1, 2, 5].
Conclusion
Guanylate cyclase activator activity (GO:0030250) is a fundamental molecular function that governs cGMP signaling in diverse physiological contexts. From cardiovascular regulation to sperm function and bone remodeling, activators of guanylate cyclase offer unique therapeutic opportunities, especially when NO signaling is compromised. The integration of CRISPR-based models with biochemical and imaging techniques will continue to unravel the complexities of this pathway, paving the way for novel treatments.
References
- 1. Revelli A et al.. 2002. Guanylate cyclase activity and sperm function.. Endocr Rev 23(4):484-94 PMID: 12202462
- 2. Hahn MG et al.. 2021. Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042).. J Med Chem 64(9):5323-5344 PMID: 33872507
- 3. McCarty MF et al.. 2022. Targeting Sirt1, AMPK, Nrf2, CK2, and Soluble Guanylate Cyclase with Nutraceuticals: A Practical Strategy for Preserving Bone Mass.. Int J Mol Sci 23(9) PMID: 35563167
- 4. Xiao S et al.. 2019. Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?. Mini Rev Med Chem 19(18):1544-1557 PMID: 31362687
- 5. Ko FN et al.. 1994. YC-1, a novel activator of platelet guanylate cyclase.. Blood 84(12):4226-33 PMID: 7527671
- 6. Petraina A et al.. 2025. Revisiting soluble guanylate cyclase pharmacology: Additive potential of stimulators and activators.. Biomed Pharmacother 193:118762 PMID: 41252787
- 7. Kimura H et al.. 1976. Appearance of magnesium guanylate cyclase activity in rat liver with sodium azide activation.. J Biol Chem 251(24):7769-73 PMID: 12177
